Hager Biosciences
Curated by SignalDiscovers small fragment molecules using its technology
Overview
Hager Biosciences is a preclinical-stage drug discovery organization. It provides therapeutic leads through out-licensing for pharmaceutical and biotech firms. It designs and synthesize proprietary small fragment molecules using its discovery FragPhore platform. It claims that the platform provides a competitive advantage for rapid medicinal properties optimization as well as intellectual property enhancement. It has received total grant of around $674k from NIH.
Key facts
- Founded
- 2008
- Headquarters
- Bethlehem, United States
- Stage
- Sign up to view
- Industry
- Health Technology
Business model
- 7 products and services
- Sign up to view
- Commercial model
- Sign up to view
Contact
- Primary office
- Sign up to view
- Sign up to view